Primary hypersomnia
Methodology & AI Transparency ⓘ
Primary hypersomnia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Primary hypersomnia is an ICD-10-CM indexed diagnosis (F51.11) within Insomnia, Sleep Apnea & Sleep Health.
- 2 Real-world patient consensus: Federal ICD-10-CM code F51.11 categorizes Primary hypersomnia under Insomnia, Sleep Apnea & Sleep Health.
- 3 Typical cash cost range: Workup highlights for Primary hypersomnia (F51.11): airway pressure or in Primary hypersomnia (F51.11: orexin-targeted therapy evaluation).
- 4 Top reported side effects / signs: Key Sleep Disorders biomarkers for Primary hypersomnia (F51.11): Apnea-Hypopnea Index (AHI) [Primary hypersomnia F51.11] & Insomnia Severity Index in Primary hypersomnia (F51.11: (ISI)) (< 7 (F51.11)).
Ask our AI Specialists anything about Primary hypersomnia
What Is Primary hypersomnia?
Primary hypersomnia is an ICD-10-CM indexed diagnosis (F51.11) within Insomnia, Sleep Apnea & Sleep Health. Clinical evaluation centers on airway pressure or in Primary hypersomnia (F51.11: orexin-targeted therapy evaluation) alongside serial Apnea-Hypopnea Index (AHI) [Primary hypersomnia F51.11] tracking (< 5 events/hour (F51.11)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Primary hypersomnia (F51.11, Sleep Disorders) reflects lateral hypothalamic orexin in Primary hypersomnia (F51.11: hyperarousal). longitudinal control is benchmarked via Apnea-Hypopnea Index (AHI) [Primary hypersomnia F51.11].
Common Symptoms & Clinical Signs
- • Presentation of Primary hypersomnia (F51.11): prolonged sleep-onset latency [Primary hypersomnia F51.11]
- • Secondary Primary hypersomnia clinical sign: unrefreshing morning waking in Primary hypersomnia (F51.11: despite adequate hours)
- • Symptom flares in Primary hypersomnia correlating with Apnea-Hypopnea Index (AHI) [Primary hypersomnia F51.11] deviation outside < 5 events/hour (F51.11)
- • Functional sleep disorders impact requiring airway pressure or in Primary hypersomnia (F51.11: orexin-targeted therapy evaluation) evaluation (F51.11)
Primary hypersomnia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F51.11 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Primary hypersomnia F51.11] | < 5 events/hour (F51.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Primary hypersomnia (F51.11: (ISI)) | < 7 (F51.11) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Primary hypersomnia (F51.11: (SpO2)) | >= 94% nadir > 90% (F51.11) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Primary hypersomnia
Treatment selection for Primary hypersomnia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Primary hypersomnia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| 7 Questions to Bring to Your Next Doctor Visit (And Why They Work) Patients who bring a simple written list of 5 to 7 focused questions get clearer answers, leave with fewer medication mix-ups, and feel far more confident about their care plan—without making the appointment run longer. BMJ Quality & Safety / Patient Education and Counseling • 2026-11-01 • Systematic Review | N = 4,820 | 96/100 | PMID 34582101 ↗ |
| New Insights on Modeling Statin-Induced Reductions of heart and blood vessel Events in Primary: What a 6,735-Participant Study Found Our results show that, in individuals without clinical ASCVD, statin therapy has the potential to reduce the frequency of CV events. Cardiology • 2018-01-15 • Meta-Analysis | N = 6,735 | 94/100 | PMID 29705799 ↗ |
| New Insights on Heart rate variability changes in patients with obstructive sleep: What a 2,565-Participant Study Found Autonomic function impairment was more serious in patients with severe obstructive sleep apnea. Journal of sleep research • 2023-02-15 • Meta-Analysis | N = 2,565 | 94/100 | PMID 36070876 ↗ |
| New Insights on Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary: What a 628-Participant Study Found Ezetimibe plus atorvastatin was well tolerated, with a safety profile similar to atorvastatin alone and to placebo. Circulation • 2003-05-20 • Randomized Controlled Trial | N = 628 | 93/100 | PMID 12719279 ↗ |
| New Insights on Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in: What a 555-Participant Study Found Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-01-15 • Phase III Randomized Trial | N = 555 | 93/100 | PMID 32770640 ↗ |
Primary hypersomnia Patient Community & “People Like Me” Threads
Filter Primary hypersomnia community threads and patient logs by age, biological sex, dosage, and treatment duration.